BioScience under the Big Sky | |
Montana BioScience Alliance Hall of Fame 2023
Our 2023 Hall of Fame inductee is Blake Wiedenheft, Ph.D., Professor of Microbiology and Cell Biology, Montana State University, Bozeman
For Dr. Blake Wiedenheft, science is the ultimate adventure. The Montana native was raised in Fort Peck, received his B.S. and Ph.D. from Montana State University in Bozeman, and is now conducting cutting-edge research from his lab at MSU.
Dr. Wiedenheft started at MSU intending to go on to medical school. However, when he met two senior professors – Dr. Trevor Douglas and Dr. Mark Young who were part of MSU’s Thermal Biology Institute – his plans changed.
“They showed me that science was more about creativity and imagination than it was about just memorization,” he said. “Seeing the way they approached science as purely an adventure and a process of discovery was what really changed the course of my career.”
An early research project for Dr. Wiedenheft involved collecting and studying microbes in Yellowstone National Park. He wanted to understand the ways that viruses manipulate their hosts, and the systems microbes use to defend themselves against infection. As a Montanan who spent as much time as he could outdoors, participating in a major research project and doing it in Yellowstone held a strong appeal. The project ultimately became the subject of his doctorate in 2006.
Click Here to Continue Reading!
| | |
Wintermute Biomedical Secures $1.3M USD Funding and Commences ZOSTER EASE Phase Ib Clinical Trial for Solexan™ in Shingles Treatment
Pioneering the way in Shingles therapy, Wintermute Biomedical initiates a Phase Ib clinical trial, backed by a successful $1.3M USD investment.
By Wintermute Biomedical
February 28, 2024
Wintermute Biomedical has successfully raised USD 1.3 million from investors to propel its groundbreaking Shingles treatment, Solexan™, into a Phase Ib clinical trial. The primary focus of this randomized double-blind placebo-controlled trial is to assess the safety, tolerability, and proof-of-concept efficacy of Solexan™ in reducing shingles-related pain and expediting lesion healing.
The ZOSTER EASE trial, initiated within expected timelines, aims to recruit 30 shingles patients in Melbourne and Sydney, Australia. Participants will topically administer either Solexan™ or an identical placebo directly to shingles lesions twice daily for ten days. As per the standard of care for shingles, patients will receive oral antivirals while applying the investigative treatment. Throughout the trial, patients will provide ongoing feedback through a shingles-specific pain questionnaire, and lesions will be documented to evaluate the treatment's impact on lesion healing.
Click Here to Continue Reading!
| | |
Four Keys to Launching a Biotech Career in Montana
By Melissa Paulsen, Montana High Tech Business Alliance, News
March 13, 2024
The Montana High Tech Business Alliance partnered with the University of Montana College of Business, University of Montana College of Humanities and Sciences, and Missoula College on February 15, 2024, to host the first UM Biotech Career Expo for University of Montana and Missoula College students, faculty, and alumni. The event introduced students to Montana employers to help them understand the specific steps they can take, and what skills are needed, to land a great internship, research position, or job in Montana’s fast-growing and high-paying biotech industry.
Tom Gallagher, dean of Missoula College, gave the opening remarks for the first career panel highlighting research, lab science, and biotechnology manufacturing. Julie Baldwin, dean of the University of Montana College of Humanities and Sciences, introduced the afternoon’s second career panel covering healthcare technology, software, and telemedicine.
The panelists included hiring managers from Bitterroot Health, FYR Diagnostics, McLaughlin Research Institute, Montana Pediatrics, PatientOne, and Rocky Mountain Biologicals. Each panelist reflected on their career journeys, shared tips to help students secure a biotech job or internship, and discussed opportunities available with their
companies for candidates eager to launch fruitful biotech careers in Montana.
Continue reading for four key takeaways from the conversation!
| | |
Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal
Press Release
April 4, 2024
Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal. The manuscript titled “Topical Pravibismane as Adjunctive Therapy for Moderate or Severe Diabetic Foot Infections: A Phase 1b Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial” is available for free download at International Wound Journal’s website (https://doi.org/10.1111/iwj.14817). The main objective of the study was to assess the safety and tolerability of adjunctive administration of topical pravibismane added to standard of care, for 2 to 3 weeks, for subjects with moderate or severely infected chronic diabetic foot ulcers (DFI). Though the study was not powered to demonstrate statistical efficacy, positive trends signalling clinical efficacy were demonstrated with pravibismane (versus placebo [vehicle]) added to standard of care, including greater reduction in wound area and lower amputation risk versus vehicle. Pravibismane is the first product in a new class of compounds that has a unique triad of novel modes of action, including potent broad spectrum anti-infective, antibiofilm, and immuno-modulatory activity.
"We are excited to share the results of this Phase 1b study that was designed mainly to assess the safety of topical pravibismane administration to DFI patients," said Dr. Benjamin A. Lipsky, Professor of Medicine Emeritus at University of Washington, and the primary author of the manuscript. “We are pleased with the safety results and signals of clinical efficacy, which we believe warrant further clinical development of pravibismane in future studies. There is currently a major unmet need for new, easy to apply drug agents with multiple modes of activity to treat infection, and possibly help close, these infected, chronic wounds.”
| | |
Montana State researcher wins prestigious NIH grant to study osteoarthritis
By Skip Anderson
March 20, 2024
A Montana State University researcher was recently awarded a $2.76 million, five-year grant from the National Institutes of Health to help find pre-symptom evidence of the onset of osteoarthritis, a disease that affects one in seven Americans.
Osteoarthritis, or OA, is an often-painful disease resulting from the breakdown of joint cartilage and the underlying bone, according to Ron June, professor of mechanical engineering in the Norm Asbjornson College of Engineering. A degenerative disease, OA is the fourth most common cause of disability globally and can often require joint-replacement surgery.
| | |
|
The faculty leaders on the project were Matthew Taylor, associate professor in the Department of Microbiology and Cell Biology, and Connie Chang, who spent nearly a decade in the Department of Chemical and Biological Engineering before taking a faculty position at the Mayo Clinic in Minnesota. Other members of the team included graduate students Jake Fredrikson, Luke Domanico and Shawna Pratt, as well as Emma Loveday, who finished her postdoctoral work while involved in the project and is now an assistant research professor in the MSU Center for Biofilm Engineering.
Click Here to Continue Reading!
| |
A neuron grown in a micro gel infected with HSV-1 that expresses a yellow fluorescent protein. Image courtesy of Matthew Taylor. | | |
UM Integrative Physiology School Opens Cancer Rehabilitation Lab
By Kyle Spurr, UM News Service
MARCH 13, 2024
At first glance, a room in the basement of McGill Hall on the University of Montana campus appears like a private gym with treadmills, dumbbells and exercise bikes.
It seems like a good place for a workout. But the space is actually a research laboratory for students and faculty in UM’s School of Integrative Physiology and Athletic Training within the College of Health.
| | |
Amanda Alfaro, an IPAT master’s student, helps run the Cardiopulmonary and Cancer Rehabilitation Lab on campus. (UM Photos by Ryan Brennecke) | |
|
For the past few years, the Cardiopulmonary and Cancer Rehabilitation Lab has housed undergraduate and graduate IPAT students who study the value of exercise for those with heart conditions and cancer diagnoses. The students helped configure the space, created educational materials and ran tests on one another with the gym equipment and ECG machines.
Later this year, the lab is planning to open to real patients who will allow the students to monitor their health.
Click Here to Continue Reading!
| | |
Two UM Researchers Earn Prestigious Early Career NSF Awards
UM researchers Beverly Piggott and Doug Brinkerhoff won early CAREER Awards from the National Science Foundation.
By Cary Shimek, UM News Service
March 20, 2024
Doug Brinkerhoff intends to use computer deep learning to improve predictions of sea level rise from melting ice sheets. Beverly Piggott will study how brain cells regulate their own acidity during development. They are the most recent University of Montana researchers to earn awards from the National Science Foundation’s Faculty Early Career Development Program.
CAREER awards are among NFS’s most prestigious honors, given to promising early career faculty members to provide a foundation for a lifetime of leadership that integrates education with research...
| | |
|
An associate professor of computer science, Dr. Brinkerhoff was awarded $626,000 for a proposal titled “Accelerating Probabilistic Predictions of Sea-Level Rise with Deep Learning.” An assistant professor of neuroscience, Dr. Piggott received $1.1 million for a project called “Bioelectric Mechanisms of Brain Development.”
He uses computer code to model the behavior of ice sheets. He said the models he works with are similar to those used to predict the weather but applied to ice rather than the atmosphere. More accurate predictions of ice sheet movement with the world’s warming climate could lead to better expectations for global sea level rise....
| |
UM researcher Doug Brinkerhoff. UM photos by Ryan Brennecke | | |
Researcher Beverly Piggott works with a student in her UM lab. UM photos by Ryan Brennecke | |
|
The other CAREER winner, Piggott, studies the bioelectrical properties of neural stem cells. Bioelectricity is well known for its role to help neurons fire and muscles contract. It is produced by electrolytes (also known as ions like sodium and potassium) fluxing between cell membranes. Proteins called ion channels regulate these fluxes. Problems or mutations in ion channels can cause neurodevelopmental disorders.
Click Here to Continue Reading!
| | |
Vision Magazine 2024 – University of Montana Research, Innovation & Imagination- Message From the Vice President
By Scott Whittenburg, UM Vice President for
Research and Creative Scholarship
March 26, 2024
Welcome to another edition of Vision, the magazine of research and creative scholarship for the University of Montana. I’m happy to report that the research enterprise at UM continues to grow. This past year we set another record for the University: Our research expenditures in fiscal year 2023 were $134 million — an $8 million increase over our previous high mark set in FY22.
Over the past decade, expenditures from research grants are up 143%, making UM one of the fastest-growing R1 universities in the country. This growth is a testament to the outstanding faculty, students and staff working here to provide innovative solutions to problems facing our state, region and world.
The University is proud of our many successful alumni, especially our own Lily Gladstone. Lily graduated from UM in 2008 with a bachelor’s degree in acting/directing. As you are probably aware, Lily became the first Native American to contend for all the major Best Actress awards this year. Inspired by her example, one of our Vision stories features the Montana Repertory Theatre play “Can’t Drink Salt Water” by UM alumna and Native playwright Kendra Mylnechuk Potter. It’s about a Native mother searching for her missing daughter and a young woman who escaped sex trafficking.
Click Here to Continue Reading!
| | |
Montana State sends 17 student researchers to premier national conference
By Reagan Cotton, MSU News Service
April 4, 2024
Montana State University will send 17 students to one of the country’s premier celebrations of undergraduate research next week, where they will have the opportunity to present the research they have done in departments across the university.
The National Conference on Undergraduate Research, or NCUR, will be held April 8-10 in Long Beach, California, and will feature undergraduate researchers from institutions nationwide.
| | |
|
“MSU has long valued undergraduate research, but prioritizing opportunities for undergraduates to participate in research is now part of the university’s strategic plan,” said Anna Tuttle, interim director of MSU’s Undergraduate Scholars Program. “These students have created this opportunity through their own motivation and work, and they made it through a rigorous application process to present at NCUR. The chance to do the research in the first place is made possible by their mentors, and we at the USP are delighted to support their trip to Long Beach.”
MSU students from the colleges of Agriculture; Arts and Architecture; Education, Health and Human Development; Letters and Science and Engineering will present their work.
Click Here to Continue Reading!
| |
From left, Wes Cousin, McKenna Quirk and Zoe Seaford are among 17 MSU students who will present research at the National Conference on Undergraduate Research. MSU photo by Marcus “Doc” Cravens. | | |
UM Research Discovers New Way To Generate Human Cartilage
By UM News Service
April 10, 2024
University of Montana researchers and their partners have found a new method to generate human cartilage of the head and neck. Mark Grimes, a biology professor in UM’s Division of Biological Sciences, said they have induced stem cells to become the cell type that normally makes up human craniofacial cartilage. Stem cells can replicate themselves and also develop into different types of cells.
“The cells that normally give rise to this type of cartilage are called neural crest cells,” Grimes said. “We found a novel method for generating craniofacial organoids from neural crest cells.” Organoids are a simplified, miniature version of an organ that mimic the architecture and gene expression of the organ. “Organoids are a good model for certain human tissues that we can study in ways that are not possible using tissue from human beings,” he said.
Grimes said there is a critical unmet need for new methods to regenerate human cartilage for the 230,000 children born annually in the U.S. with craniofacial defects. Growing cartilage in the laboratory also could lead to effective treatments to repair craniofacial cartilage damage due to injuries.
Click Here to Continue Reading!
| | |
NIH Scientists Find Weak Points on Epstein-Barr Virus
New Details of EBV Protein Could Aid Treatment, Prevention Efforts
Press Release
March 12, 2024
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus. The research was led by Jeffrey I. Cohen, M.D., and colleagues from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Study findings were published in the journal Immunity.
Approximately 95% of the world’s population is infected with EBV, which remains in the body permanently, typically in B lymphocytes, which are antibody-producing immune system cells, and cells lining the throat and pharynx. EBV can sometimes lead to B-cell cancers, including Burkitt, Hodgkin and non-Hodgkin lymphomas, or to gastric or nasopharyngeal cancers. Recently, EBV infection was shown to significantly raise the risk of developing multiple sclerosis. There is no vaccine to prevent EBV infection nor a specific treatment.
In this study, NIAID investigators examined a viral protein called gp42, which the virus must use to infect B cells. Theoretically, a vaccine or antibody-based treatment capable of blocking gp42’s ability to bind to or fuse with B cells would prevent EBV infection and, thus, the virus’s ability to persist in those cells. The team generated two gp42-specific mAbs, A10 and 4C12, and used X-ray crystallography to visualize how they interacted with gp42. The crystal structures revealed that the two mAbs interacted with distinct, non-overlapping sites on gp42. Monoclonal antibody A10 blocked the site on gp42 required for receptor binding, while 4C12 interfered with a different site that is involved in membrane fusion.
Click Here to Continue Reading!
| | |
|
Cassanda Sunell represented the Montana BioScience Alliance at South by Southwest in Austin Texas, in early March. Special thanks to Bonaventure Equity LLC for hosting.
Greetings from Bonaventure Equity, LLC's inaugural SXSW adventure! Our Austin Roadshow featured Managing Partner Ross O'Brien, BVE Portfolio Companies - FloraWorks and Nalu Bio - BVE Leadership and valued partners like Montana Bio Science, MensBrainHealth.org, TD Foundation and the Legacy Alliance.
We are proud to collaborate with such distinguished partners and industry icons and innovators. It was our esteemed privilege to welcome Jean Oelwang, President and Founding CEO of Virgin Unite, Co-Founder of Plus Wonder, and Author of Partnering, as our guest of honor, with a curated conversation exploring how to forge deep connections that make great things happen. Thank you to all of our investors, attendees, and visionary leaders who engaged in dynamic discussions around the new generation of innovative health sciences, the power of partnerships and the future of healthcare.
| | |
|
Montana Bioscience Alliance hosted Healthcare Immersion Day for Local High School Students Seeking Futures in Health-Related Fields
The Montana Bioscience Alliance and industry partners are proud to announce the Successful 2024 Immersion Day at Rocky Vista University (4130 Rocky Vista Way, Billings, MT and both local hospitals; Billings Clinic and Intermountain Health on February 23, 2024. The Immersion Day follows the Careers in Healthcare Student Summit, hosted at Montana State University Billings, October 27, 2023. These events are designed to showcase a wide range of healthcare occupations to high school students, encouraging them to explore all the career possibilities that await them. During the Immersion Day, students arrived at Rocky Vista University and spent the morning in the Medical Simulation Labs, observing Osteopathic Manipulation Medicine and Ultrasound Labs. After lunch at RVU they dispersed to hospitals throughout Billings, MT for an afternoon of job shadowing.
| | |
|
Montana BioScience Alliance is looking forward to Montana World Trade Center’s World Trade & Investment Day 2024!
This premier event, held on May 22nd at Montana State University, will feature content particularly useful to Montana’s technology-based exporters and will bring together industry leaders, global trade experts, and business professionals for a day of insightful discussions, networking, and celebration of Montana's export achievements. Subject matter experts from the U.S. Patent & Trademark Office, EXIM Bank, SBA, and others will also be on site offering 1:1 counseling sessions the morning of May 22 before the formal program begins. Come glean global trade insights to help you shape your international expansion from best-in-class presenters and your industry peers. Use code BIO to receive a 10% discount on registration.
Registration:
Register now to secure your spot! Visit www.mwtc.org or bit.ly/wtid2024 for more information and registration details.
| | |
|
Rocky Mountain Life Sciences Investor and Partnering Conference
Thursday, September 12 — Friday, September 13
Beaver Run Resort & Conference Center | 620 Village Road | Breckenridge, CO
Registration is open for CBSA’s 2024 Rocky Mountain Life Sciences Investor and Partnering Conference!
With so much interest in this event, we have outgrown the venue in Vail and are moving the conference to a newly renovated, spacious venue in Breckenridge, Colorado with a fresh conference format.
The event will kick-off with a keynote lunch on September 12, and end by noon on September 13.
For more information, or if you have interest in sponsoring, contact Emily Martini, Vice President of Partnerships.
| | |
Employment and Funding Opportunities | | |
Administrative Supplements to Promote Diversity in Research and Development Small Businesses - SBIR/STTR
Are you interested in supporting more diversity and inclusion in your biotechnology? The National Institute on Aging (NIA) Small Business Program is accepting applications for Diversity Supplements, which are administrative funds (up to $250,000 in direct costs) to enhance the research and entrepreneurial workforce's diversity by recruiting and supporting students, post-docs, and eligible investigators from underrepresented groups in health-related research into the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
Scientists, entrepreneurs, and trainees from diverse backgrounds and life experiences bring unique perspectives, creativity, and individual enterprise to address complex scientific problems. Participation by minority, socially and economically disadvantaged, and women-owned small businesses is critical to the success of the SBIR and STTR programs as well as to the development of new treatments, technologies, and products that address healthy aging. NIA strives to identify, develop, and support researchers by fostering diversity in the workforce through the SBIR and STTR programs and encourages you to consider applying for the Administrative Supplements to Promote Diversity in Research and Development Small Businesses - SBIR/STTR.
- Deadline: NIA accepts applications on a rolling basis. Applications received by the second Thursday of the month will be reviewed the following month. Applications received after the second Thursday of the month will be reviewed within two months.
- Eligibility: Phase I and Phase II SBIR and STTR applicants are encouraged to apply for diversity supplements. At the time of supplement application, parent SBIR and STTR grants must have a minimum of 8 months remaining to ensure sufficient time and opportunity for diversity-based candidates to gain experience.
- Candidates: High school, undergraduate, post-baccalaureate, master’s, Ph.D., postdoctoral, and eligible new investigator candidates from groups that are underrepresented in biomedical research, such as individuals from underrepresented racial/ethnic groups, with a disability, or from disadvantaged backgrounds.
Thank you again for your interest in the NIA SBIR and STTR programs. Please follow us on LinkedIn and Twitter to join the conversation and our NIA Small Business community. For more information, please contact Armineh Ghazarian.
| | |
|
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The application due dates are January 5th, April 5th and September 5th, so start preparing your application today. As usual, there are four Omnibus Solicitations:
-
PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
-
PA-23-231: PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
-
PA-23-232: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
-
PA-23-233: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
Please note: The SBIR and STTR Extension Act of 2022 (the Act), signed into law by President Biden on September 30, 2022, reauthorized the SBIR program, the STTR program, and related pilot programs through September 30, 2025.
The Act includes major changes to the SBIR and STTR programs, including:
Additionally, peer review criteria have changed. As these are significant changes, applicants are urged to read the solicitations in full.
Questions? Contact SEEDinfo@nih.gov.
| | |
|
2024 FAST Micro-Grants are here!
The Montana Innovation Partnership (MTIP) powered by MSU TechLink Center will utilize some of our 2024 FAST funds to provide financial assistance to Montana small businesses that are actively preparing SBIR/STTR proposals in the federal fiscal year 2024.
The costs to apply for an SBIR/STTR grant or contract can be considerable. Financial assistance for early-stage companies increases their participation in the SBIR program and the quality of their proposals.
MTIP will award six FAST Microgrants to eligible SBIR/STTR applicants of up to $2,000 per year. Prospective SBIR/STTR applicants may apply to MTIP to receive Microgrants to attend conferences, travel to speak with agencies or commercialization partners, to acquire consulting services from an approved service provider for assistance with preparation of Phase I or Phase II proposals, to develop supporting project data, and to undertake other activities directly related to their SBIR/STTR proposal.
For more information and to access the application
Click Here!
| | |
Careers at Mesa
Our 500+ employees do work that matters in following our purpose Protecting the Vulnerable®, applying our skills in ways that make a positive impact. That work is accomplished by rallying behind Mesa’s vision: a customer-focused, lean-based value system, called The Mesa Way! and is based on four pillars that drive our work every day- Measure What Matters, Empower Teams, Steadily Improve, and Always Learn
| | |
Careers at Inimmune
Join the Inimmune team in beautiful Missoula, Montana. Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology.We are always looking for talented people. If we do not have any available positions posted, contact us directly to inquire.
Send your Resume
Inimmune is always interested in creative, enthusiastic scientists with experience in synthetic chemistry, formulation and analytical development, or immunology. If you would like to be part of our team, please email your resume to HR@Inimmune.com
To find out more about the current open positions and about Inimmune, Click Here!
| | |
|
Careers at FYR Diagnostics
FYR Diagnostics is a fast growing Missoula, MT-based biotechnology company developing a powerful portfolio of PCR-focused solutions. FYR Diagnostics’ mission is to commercialize novel detection technologies to help eliminate human suffering by better diagnosing human disease states and to eliminate vast inefficiencies in the agricultural industry.
Those who work with FYR Diagnostics are members of a community that seeks to respect and celebrate all the qualities that make each of us unique. Each of us is empowered to be ourselves within this community, which cultivates and promotes equity, diversity, and inclusion at all levels. FYR Diagnostics is proud to be an Equal Opportunity Workplace and Affirmative Action Employer.
Open Positions:
To find out more about the current open positions, Click Here!
| | |
|
Two Bear Capital provides a job board with the different job openings from
the following companies:
-Abilita Bio
-CIQ
-Elisity
-FYR Diagnostics
-Graphiant
-Inimmune
-Novoron Bioscience
-pulseData
-Selector AI
-TileDB
For Open positions with Companies you'll love to work for, Click Here!
| | |
|
Work for a great company in beautiful Bozeman, MT
At Golden Helix, we are committed to accelerating ground-breaking research in genetics, drug discovery and predictive analytics, to our purpose of dramatically improving human health, our great culture, personal development, and strong values.
We are always seeking self-motivated individuals who strive for excellence and have the drive to help us on our journey. We offer competitive wages, benefits and the opportunity to live in one of the most beautiful areas in the world.
Open Positions:
-Area Sales Director
-Director of Renewal Sales
-Finance Manager
-Operations Coordinator
General Employment Inquiries
Interested in a position that we're not actively hiring? Submit your resume for our files! We will archive your information and if a position becomes available that matches your qualifications, we'll contact you.
Click here to apply!
| | |
GSK Hamilton
The Hamilton site is located on a 35-acre campus in the heart of the scenic Bitterroot Valley of western Montana. It started in 1981 as Ribi ImmunoChem Research, Inc., a company focused on research and development of vaccine components capable of stimulating the immune system. GSK purchased the site in 2005 to acquire its proprietary adjuvant technology which is used to help make vaccines more effective. GSK Hamilton currently employs over 185 professionals and is expanding its job base with the addition of a new adjuvant manufacturing facility.
To review current openings at the GSK Hamilton (GlaxoSmithKline) site, Click Here!
| | |
|
Open Solicitations From Techlink and MTIP
Dates are subject to change. Please refer to each agency site for up-to-date information.
-
NIH Targeted funding announcements have varying release and due dates. Find a list of currently open program announcements and requests for applications here.
Identify a participating agency or agencies interested in your topic area, Click Here.
Different participating agencies fund different sectors and technology areas, so a first step is to see which agency or agencies fund projects relevant to you. Agencies also differ in how narrow or broadly they define their topic areas. Current Topics - Search technology topic areas that agencies are interested in funding right now.
Reach out today for no-cost consulting and proposal reviews from one of MTIP's SBIR
experts.
| | |
|
Montana SBIR/STTR Matching Funds Program
What do you do after you have received Stage 1 SBIR/STTR matching funds from the Montana Department of Commerce, have satisfactorily completed your Phase I work, the Phase I final report has been accepted by the Federal SBIR/STTR agency, and you have submitted your SBIR or STTR Phase II proposal?
You submit your Stage 2 application to the Montana SBIR/STTR Matching Funds Program. You do not have to receive notification of a Phase II award before submitting this application. For more information, Click Here!
Questions? Feel free to contact Ann at ann.peterson@montana.edu or
Annmarie Robinson with the Department of Commerce at arobinson3@mt.gov.
| | |
How would you like to have more free time to focus on innovating and growing your business?
Are you ready to clear your plate of time-consuming daily HR tasks — such as payroll, benefits, talent, and compliance? Right now's the perfect time to see if ADP’s PEO is the right move for you, too.
What is ADP TotalSource?
- Endorsed by BIO for life science companies of any size.
- Full-service PEO (professional employer organization) partner with coverage in all 50 states
- Partner to help you attract and retain top talent more easily with access to ADP Recruiters, HR advisors and best-in-class benefits.
- Industry-leading PEO, giving you confidence that ADP does it the right way.
As an IRS certified and ESAC accredited PEO, ADP meets the highest standards for financial responsibility, ethical business conduct, and regulatory compliance.
Now is the time to start the process if you want to make a change for 2024.
| | |
|
UPS Healthcare brings reliability, scalability and security to life science companies every day. Its portfolio of end-to-end services is well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Learn exactly how from UPS Healthcare.
Through Montana BioScience Alliance’s partnership with UPS Healthcare, you get access to exclusive rates on a full suite of UPS® services. And, after recent renegotiations, the savings have gotten even better. While the same popular shipping services, like UPS Next Day Air®, and UPS Worldwide Express SM, remain at reduced rates, the price band range to qualify for discounts is narrower. For example, a company that spends $1,500 to $4,999.99 weekly for UPS Next Day Air® shipping now receives a 60% discount rather than a 50-55% discount under the previous arrangement.
As a Montana BioScience Alliance member, be confident that your critical healthcare shipments will be delivered timely and with care by a quality-focused and patient-driven organization.
Montana BioScience Alliance Members Save Up To:
· 74% on UPS Next Day Air®
· 59% on UPS 2nd Day Air® & UPS 3 Day Select Services®
· 51% on UPS Ground® Commercial Services
· 68% on UPS Worldwide International Services
| | |
BIO Business Solutions®, the largest cost-savings program for the life sciences industry, is FREE with your company’s membership in BIO or Montana BioScience Alliance. Receiving savings from our lab and office partners is incredibly simple. We’ve already vetted the suppliers and negotiated discounted pricing and favorable end-user agreements.
Click on the company name to learn more.
There is no fee for MBA members to participate.
| | |
|
The Montana Bioscience Alliance serves as a hub for Montana's biotechnology companies,
entrepreneurs, laboratories, hospitals, clinics and universities to commercialize, grow and sustain
globally competitive bioscience companies -- ultimately to create high-quality jobs and economic
opportunity in Montana.
Sharon Peterson
Executive Director
Montana BioScience Alliance
sharonpeterson@bresnan.net
| | | | |
